A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

Purpose: Metastatic pancreatic adenocarcinoma (mPC) has a poor prognosis. CDK4/6 is often deregulated in mPC due to CDKN2A loss, resulting in the loss of p16INK4a that inhibits CDK4/6. CDK4/6 inhibitor monotherapy is ineffective due to RAS-mediated activation of alternative pathways, including phosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinberg, Benjamin A., Wang, Hongkun, Witkiewicz, Agnieszka K., Marshall, John L., He, Aiwu R., Vail, Paris, Knudsen, Erik S., Pishvaian, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337242/
https://www.ncbi.nlm.nih.gov/pubmed/32642630
http://dx.doi.org/10.1089/pancan.2020.0005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337242/
https://www.ncbi.nlm.nih.gov/pubmed/32642630
http://dx.doi.org/10.1089/pancan.2020.0005

Ejemplares similares